MX371033B - Productos farmacéuticos mejorados de péptido para resistencia a la insulina. - Google Patents
Productos farmacéuticos mejorados de péptido para resistencia a la insulina.Info
- Publication number
- MX371033B MX371033B MX2016015594A MX2016015594A MX371033B MX 371033 B MX371033 B MX 371033B MX 2016015594 A MX2016015594 A MX 2016015594A MX 2016015594 A MX2016015594 A MX 2016015594A MX 371033 B MX371033 B MX 371033B
- Authority
- MX
- Mexico
- Prior art keywords
- insulin resistance
- improved peptide
- peptide pharmaceuticals
- pharmaceuticals
- modified peptides
- Prior art date
Links
- 239000003814 drug Substances 0.000 title abstract 2
- 108090000765 processed proteins & peptides Proteins 0.000 title abstract 2
- 206010022489 Insulin Resistance Diseases 0.000 title 1
- 208000001072 type 2 diabetes mellitus Diseases 0.000 title 1
- 102000004169 proteins and genes Human genes 0.000 abstract 3
- 108091005601 modified peptides Proteins 0.000 abstract 2
- 108091005573 modified proteins Proteins 0.000 abstract 2
- 238000000034 method Methods 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 238000003786 synthesis reaction Methods 0.000 abstract 1
- 230000001225 therapeutic effect Effects 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/605—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
- A61K47/549—Sugars, nucleosides, nucleotides or nucleic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
- A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
- A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
- A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/02—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids
- C07H13/04—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by carboxylic acids having the esterifying carboxyl radicals attached to acyclic carbon atoms
- C07H13/06—Fatty acids
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
- C07H13/00—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids
- C07H13/12—Compounds containing saccharide radicals esterified by carbonic acid or derivatives thereof, or by organic acids, e.g. phosphonic acids by acids having the group -X-C(=X)-X-, or halides thereof, in which each X means nitrogen, oxygen, sulfur, selenium or tellurium, e.g. carbonic acid, carbamic acid
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
- Y02P20/00—Technologies relating to chemical industry
- Y02P20/50—Improvements relating to the production of bulk chemicals
- Y02P20/55—Design of synthesis routes, e.g. reducing the use of auxiliary or protecting groups
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Diabetes (AREA)
- Molecular Biology (AREA)
- Endocrinology (AREA)
- Biochemistry (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Cardiology (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Immunology (AREA)
- Emergency Medicine (AREA)
- Toxicology (AREA)
- Urology & Nephrology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Biotechnology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invención se refiere a métodos de síntesis y usos terapéuticos de péptidos y/o proteínas modificados covalentemente. Los péptidos y/o proteínas modificados covalentemente permiten propiedades farmacéuticas mejoradas de productos terapéuticos a base de péptido y/o proteína.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201462004156P | 2014-05-28 | 2014-05-28 | |
PCT/US2015/033042 WO2015184177A1 (en) | 2014-05-28 | 2015-05-28 | Improved peptide pharmaceuticals for insulin resistance |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2016015594A MX2016015594A (es) | 2017-03-23 |
MX371033B true MX371033B (es) | 2020-01-13 |
Family
ID=54699825
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016015594A MX371033B (es) | 2014-05-28 | 2015-05-28 | Productos farmacéuticos mejorados de péptido para resistencia a la insulina. |
Country Status (16)
Country | Link |
---|---|
US (3) | US9856306B2 (es) |
EP (1) | EP3155017B1 (es) |
JP (3) | JP6697807B2 (es) |
KR (2) | KR20230084337A (es) |
CN (5) | CN113264994A (es) |
AU (3) | AU2015266854B2 (es) |
BR (1) | BR112016027595B1 (es) |
CA (1) | CA2949701C (es) |
DK (1) | DK3155017T3 (es) |
FI (1) | FI3155017T3 (es) |
IL (3) | IL249044B (es) |
MX (1) | MX371033B (es) |
NZ (2) | NZ726623A (es) |
PL (1) | PL3155017T4 (es) |
PT (1) | PT3155017T (es) |
WO (1) | WO2015184177A1 (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2012158964A2 (en) | 2011-05-18 | 2012-11-22 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals for osteoporosis |
CA3134906A1 (en) | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
EP4047023A1 (en) | 2012-11-20 | 2022-08-24 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
KR102365582B1 (ko) | 2012-11-20 | 2022-02-18 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
CN113264994A (zh) | 2014-05-28 | 2021-08-17 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
EP3654941A1 (en) | 2017-07-17 | 2020-05-27 | Keith Roizman | Topical delivery of therapeutic agents comprising cell-penetrating peptides for use for the treatment of age-related macular degeneration and other eye diseases |
BR112020013644A2 (pt) * | 2018-01-03 | 2020-12-01 | Mederis Diabetes, Llc | produto de peptídeo ou sal farmaceuticamente aceitável do mesmo para uso no tratamento de síndrome de ovário policístico, um distúrbio renal ou um distúrbio hepático, e, kit. |
MX2022010320A (es) * | 2020-02-21 | 2023-01-30 | Spitfire Pharma Llc | Agonistas, formulaciones y metodos de uso de glp-1r y gcgr. |
JP2024500324A (ja) * | 2020-12-07 | 2024-01-09 | スピットファイア ファーマ エルエルシー | Glp-1rおよびgcgr均衡アゴニストを使用した血糖および/または体重を低下させるための治療レジメンおよび方法 |
CN117202924A (zh) * | 2020-12-07 | 2023-12-08 | 斯皮特弗尔制药有限责任公司 | 使用glp-1r和gcgr平衡激动剂降低血糖和/或体重的治疗方案和方法 |
CN113461747B (zh) * | 2021-07-12 | 2023-02-03 | 吉林化工学院 | 刺玫果中2个具有降血糖活性的化合物 |
Family Cites Families (50)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3219656A (en) | 1963-08-12 | 1965-11-23 | Rohm & Haas | Alkylpolyalkoxyalkyl glucosides and process of preparation therefor |
US3839318A (en) | 1970-09-27 | 1974-10-01 | Rohm & Haas | Process for preparation of alkyl glucosides and alkyl oligosaccharides |
US4179337A (en) | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
JPS6023084B2 (ja) | 1979-07-11 | 1985-06-05 | 味の素株式会社 | 代用血液 |
US4675189A (en) | 1980-11-18 | 1987-06-23 | Syntex (U.S.A.) Inc. | Microencapsulation of water soluble active polypeptides |
US4640835A (en) | 1981-10-30 | 1987-02-03 | Nippon Chemiphar Company, Ltd. | Plasminogen activator derivatives |
US4496689A (en) | 1983-12-27 | 1985-01-29 | Miles Laboratories, Inc. | Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer |
DK149776C (da) | 1984-01-06 | 1987-04-21 | Orion Yhtymae Oy | Antibiotisk virksom erytromycinforbindelse og praeparat indeholdende forbindelsen |
AT382381B (de) | 1984-10-02 | 1987-02-25 | Oesterr Zuckerfab Evidenz | Verfahren zur herstellung neuer grenzfl|chenaktiver kohlenhydrat-derivate |
EP0206448B1 (en) | 1985-06-19 | 1990-11-14 | Ajinomoto Co., Inc. | Hemoglobin combined with a poly(alkylene oxide) |
US4791192A (en) | 1986-06-26 | 1988-12-13 | Takeda Chemical Industries, Ltd. | Chemically modified protein with polyethyleneglycol |
US5252318A (en) | 1990-06-15 | 1993-10-12 | Allergan, Inc. | Reversible gelation compositions and methods of use |
US5574142A (en) | 1992-12-15 | 1996-11-12 | Microprobe Corporation | Peptide linkers for improved oligonucleotide delivery |
US5661130A (en) | 1993-06-24 | 1997-08-26 | The Uab Research Foundation | Absorption enhancers for drug administration |
JPH1160598A (ja) | 1997-08-15 | 1999-03-02 | Asahi Glass Co Ltd | オピオイド様ペプチド |
US6720407B1 (en) | 1998-08-28 | 2004-04-13 | Eli Lilly And Company | Method for administering insulinotropic peptides |
US6924264B1 (en) | 1999-04-30 | 2005-08-02 | Amylin Pharmaceuticals, Inc. | Modified exendins and exendin agonists |
US6309633B1 (en) | 1999-06-19 | 2001-10-30 | Nobex Corporation | Amphiphilic drug-oligomer conjugates with hydroyzable lipophile components and methods for making and using the same |
RU2181729C1 (ru) | 2000-09-20 | 2002-04-27 | Калюжин Олег Витальевич | Производные мурамовой кислоты |
US6858580B2 (en) | 2001-06-04 | 2005-02-22 | Nobex Corporation | Mixtures of drug-oligomer conjugates comprising polyalkylene glycol, uses thereof, and methods of making same |
US6835802B2 (en) | 2001-06-04 | 2004-12-28 | Nobex Corporation | Methods of synthesizing substantially monodispersed mixtures of polymers having polyethylene glycol moieties |
US6864069B2 (en) | 2001-10-05 | 2005-03-08 | Bayer Pharmaceuticals Corporation | Peptides acting as both GLP-1 receptor agonists and glucagon receptor antagonists and their pharmacological methods of use |
ES2411007T3 (es) | 2001-10-10 | 2013-07-04 | Novo Nordisk A/S | Remodelación y glicoconjugación de péptidos |
US6881829B2 (en) | 2002-04-26 | 2005-04-19 | Chimeracom, L.L.C. | Chimeric hybrid analgesics |
US20110257096A1 (en) | 2004-08-25 | 2011-10-20 | Aegis Therapeutics, Inc. | Compositions for drug administration |
US20060046962A1 (en) | 2004-08-25 | 2006-03-02 | Aegis Therapeutics Llc | Absorption enhancers for drug administration |
ITRM20040607A1 (it) | 2004-12-15 | 2005-03-15 | Biogen S R L | Analoghi della dermorfina ad attivita' analgesica. |
US7776819B2 (en) | 2005-03-03 | 2010-08-17 | The Board Of Trustees Of The University Of Illinois | Targeted drug delivery of pain and addiction therapies using opioid receptor-mediated internalization |
EP1883419A4 (en) * | 2005-05-06 | 2010-08-04 | Bayer Pharmaceuticals Corp | GLUCAGON-LIKE PEPTIDE-1 (GLP-1) RECEPTOR AGONISTS AND THEIR PHARMACOLOGICAL USES |
US7390788B2 (en) | 2005-06-23 | 2008-06-24 | Pert Candace B | Peptide pharmaceutical compositions |
EP1767545B1 (en) | 2005-09-22 | 2009-11-11 | Biocompatibles UK Limited | GLP-1 (Glucagon-like peptide-1) fusion polypeptides with increased peptidase resistance |
WO2007060692A2 (en) | 2005-11-24 | 2007-05-31 | Brain N' Beyond Biotech Pvt. Ltd. | Compositions for increasing bioavailability of peptides or proteins and method thereof |
US7998927B2 (en) | 2006-06-23 | 2011-08-16 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
US8173594B2 (en) | 2006-06-23 | 2012-05-08 | Aegis Therapeutics, Llc | Stabilizing alkylglycoside compositions and methods thereof |
WO2008052043A2 (en) | 2006-10-24 | 2008-05-02 | Cogenesys, Inc. | Opioid receptor agonist fusion proteins |
EP1961765A1 (en) | 2006-12-08 | 2008-08-27 | Zealand Pharma A/S | Truncated PTH peptides with a cyclic conformation |
MX2009008241A (es) | 2007-02-15 | 2009-10-08 | Univ Indiana Res & Tech Corp | Co-agonistas de receptor de glucagon/glp-1. |
MX2010013454A (es) * | 2008-06-17 | 2011-01-21 | Tion Indiana University Res And Technology Corpora | Co-agonistas de receptor de glucagon/glp-1. |
SI2454282T1 (sl) | 2009-07-13 | 2015-06-30 | Zealand Pharma A/S | Acilirani glukagonski analogi |
US8221753B2 (en) | 2009-09-30 | 2012-07-17 | Tracon Pharmaceuticals, Inc. | Endoglin antibodies |
NZ612297A (en) | 2010-12-22 | 2015-10-30 | Univ Indiana Res & Tech Corp | Glucagon analogs exhibiting gip receptor activity |
KR101453037B1 (ko) | 2011-03-23 | 2014-10-21 | 주식회사 엘지화학 | 전극조립체 및 이의 제조방법 |
CA3134906A1 (en) | 2011-05-18 | 2012-11-22 | Mederis Diabetes, Llc | Improved peptide pharmaceuticals for insulin resistance |
WO2012158964A2 (en) | 2011-05-18 | 2012-11-22 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals for osteoporosis |
KR102365582B1 (ko) | 2012-11-20 | 2022-02-18 | 메더리스 다이어비티즈, 엘엘씨 | 인슐린 저항성에 대한 개선된 펩티드 약제 |
EP4047023A1 (en) * | 2012-11-20 | 2022-08-24 | Eumederis Pharmaceuticals, Inc. | Improved peptide pharmaceuticals |
AU2014255608B2 (en) * | 2013-04-18 | 2018-01-25 | Novo Nordisk A/S | Stable, protracted GLP-1/glucagon receptor co-agonists for medical use |
CN113264994A (zh) | 2014-05-28 | 2021-08-17 | 梅德瑞斯糖尿病有限责任公司 | 针对胰岛素抵抗的改良肽药物 |
MD20170055A2 (ro) * | 2014-10-24 | 2017-09-30 | Merck Sharp & Dohme Corp | Co-agonişti ai receptorilor glucagonului şi GLP-1 |
BR112020013644A2 (pt) * | 2018-01-03 | 2020-12-01 | Mederis Diabetes, Llc | produto de peptídeo ou sal farmaceuticamente aceitável do mesmo para uso no tratamento de síndrome de ovário policístico, um distúrbio renal ou um distúrbio hepático, e, kit. |
-
2015
- 2015-05-28 CN CN202011222645.1A patent/CN113264994A/zh active Pending
- 2015-05-28 CA CA2949701A patent/CA2949701C/en active Active
- 2015-05-28 KR KR1020237018945A patent/KR20230084337A/ko not_active Application Discontinuation
- 2015-05-28 PT PT157989567T patent/PT3155017T/pt unknown
- 2015-05-28 JP JP2016569787A patent/JP6697807B2/ja active Active
- 2015-05-28 KR KR1020167036463A patent/KR102542164B1/ko active IP Right Grant
- 2015-05-28 NZ NZ726623A patent/NZ726623A/en unknown
- 2015-05-28 CN CN201580041790.0A patent/CN106661097A/zh active Pending
- 2015-05-28 CN CN202311098595.4A patent/CN117180445A/zh active Pending
- 2015-05-28 AU AU2015266854A patent/AU2015266854B2/en active Active
- 2015-05-28 CN CN202311098620.9A patent/CN117582516A/zh active Pending
- 2015-05-28 NZ NZ757113A patent/NZ757113A/en unknown
- 2015-05-28 BR BR112016027595-0A patent/BR112016027595B1/pt active IP Right Grant
- 2015-05-28 US US15/314,466 patent/US9856306B2/en active Active
- 2015-05-28 DK DK15798956.7T patent/DK3155017T3/da active
- 2015-05-28 CN CN201910116865.7A patent/CN109865142A/zh active Pending
- 2015-05-28 EP EP15798956.7A patent/EP3155017B1/en active Active
- 2015-05-28 MX MX2016015594A patent/MX371033B/es active IP Right Grant
- 2015-05-28 WO PCT/US2015/033042 patent/WO2015184177A1/en active Application Filing
- 2015-05-28 FI FIEP15798956.7T patent/FI3155017T3/fi active
- 2015-05-28 PL PL15798956.7T patent/PL3155017T4/pl unknown
-
2016
- 2016-11-17 IL IL249044A patent/IL249044B/en active IP Right Grant
-
2017
- 2017-11-21 US US15/820,127 patent/US10577405B2/en active Active
-
2020
- 2020-01-21 US US16/747,759 patent/US20200277351A1/en active Pending
- 2020-04-21 JP JP2020075470A patent/JP2020143066A/ja active Pending
- 2020-06-02 AU AU2020203609A patent/AU2020203609B2/en active Active
- 2020-06-21 IL IL275526A patent/IL275526B/en unknown
-
2021
- 2021-08-15 IL IL285613A patent/IL285613A/en unknown
-
2022
- 2022-08-09 JP JP2022127266A patent/JP2022172128A/ja active Pending
-
2023
- 2023-02-08 AU AU2023200659A patent/AU2023200659A1/en active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MX2018013981A (es) | Productos farmaceuticos peptidicos mejorados para la resistencia a la insulina. | |
MX2016015594A (es) | Productos farmaceuticos mejorados de peptido para resistencia a la insulina. | |
MX344219B (es) | Productos farmaceuticos peptidicos mejorados para resistencia a insulina. | |
EP4286400A3 (en) | Improved peptide pharmaceuticals | |
IL251462A0 (en) | Pharmaceutical formulations for oral administration of peptide or protein drugs | |
CY1122803T1 (el) | Διαδικασιες γραμμης παραγωγης σπορων και χρησεις αυτων | |
BR112018072783A2 (pt) | proteínas de fusão elp para liberação controlada e retardada | |
EP3490538A4 (en) | PARTICLES FOR THE ADMINISTRATION OF PROTEINS AND PEPTIDES | |
HK1247831A1 (zh) | 蛋白質或肽傳遞用的可溶性微針 | |
EP3538542A4 (en) | CYCLIC PEPTIDIC MULTIMERS TARGETING ALPHA4BETA7 INTEGRIN | |
EP3568468A4 (en) | RECOMBINATION PRODUCTS TARGETING PEPTIDE HISTONE H3 / MHC COMPLEXES AND THEIR USES | |
HK1248729A1 (zh) | 細胞毒性hexim1肽和其用途 | |
IL252902A0 (en) | Amino acid and peptide conjugates and their uses | |
ZA202004658B (en) | Pharmaceutical composition comprising an apl type peptide | |
MX2019013124A (es) | Proteinas de fusion de inhibidor de tripsina urinaria (uti). | |
ZA201903657B (en) | Ras protein degradation inducing molecule and pharmaceutical composition | |
EP3186272A4 (en) | Functionalized beta-sheet peptide stabilized membrane proteins, constructs comprising same, and methods of forming and using same | |
EP3419962A4 (en) | AMINO ACID AND PEPTIDE CONJUGATES AND CONJUGATION METHOD | |
EP3491009A4 (en) | PROTEIN EXPRESSION AMPLIFIER SEQUENCES AND USE THEREOF | |
ZA201904386B (en) | S-arrestin peptides and therapeutic uses thereof | |
EP3474826A4 (en) | PHARMACEUTICAL PREPARATION FOR ADMINISTRATION OF PEPTIDES AND PROTEINS | |
AU2017305946A8 (en) | C1q and HMGB1 fusion proteins and uses thereof | |
EP3345003A4 (en) | IDENTIFICATION OF PROTEINS IN THE ABSENCE OF PEPTIDE IDENTIFICATION | |
MX2017003949A (es) | Derivados peptidicos novedosos y sus usos. | |
NZ746677A (en) | Novel alpha-1-microglobulin derived proteins and their use |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |